INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT CHLOROPHYLLIPT

Composition:

Active substance: 1 container contains 30 mg of chlorophyllipt extract, thick (10.76:1) (extractant ethanol 93%);

Excipients: methylparahydroxybenzoate (E 218), propylparahydroxybenzoate (E 216), ethanol (96%), glycerol, polysorbate (polysorbate-80), purified water.

Pharmaceutical form. Spray.

Main physicochemical characteristics: opalescent liquid, light green to green in color, with a specific odor.

Pharmacotherapeutic group. Antiseptics and disinfectants. ATC code D08AX.

Pharmacological properties.

Pharmacodynamics.

Chlorophyllipt is a mixture of chlorophylls derived from eucalyptus leaves. The drug exerts antibacterial (bacteriostatic and bactericidal) activity against staphylococci, as well as demonstrates antiseptic and anti-inflammatory properties.

Pharmacokinetics.

Not studied.

Clinical characteristics.

Indications.

Treatment of diseases caused by antibiotic-resistant staphylococci: cervical erosion, burns, trophic ulcers, acute respiratory diseases (ARD), anginas.

Contraindications. Hypersensitivity to the components of the drug.

Interaction with other medicinal products and other types of interactions. Enhances the effect of antiseptic agents.

Special precautions for use.

Consult a physician before starting treatment.

After the first application, a pause of 6–8 hours is recommended. Course treatment with the drug may be initiated only after confirming the absence of allergic reactions to the dense chlorophyllipt extract (risk of lip swelling, mucosal edema of the nose, pharynx, and other allergic reactions). If any of the above symptoms occur, discontinue use of the drug and consult a physician.

The presence of methylparahydroxybenzoate and propylparahydroxybenzoate in the formulation may cause allergic reactions (possibly delayed).

Use during pregnancy or breastfeeding. The efficacy and safety of the drug during pregnancy or breastfeeding have not been studied; therefore, the drug should not be used in these patient groups.

Ability to affect reaction rate when driving or operating machinery. No effect.

Method of Administration and Dosage.

Chlorophyllipt is intended for topical use. In inflammatory conditions of the upper respiratory tract (tonsillitis, acute respiratory diseases), adults should spray the throat with 2 sprays 3–4 times a day for 3–4 days. For the treatment of erosions, trophic ulcers, and burns, moisten a gauze pad with the preparation and leave it on the skin or mucous membrane surface for 15–20 minutes. Perform the procedure twice daily. Repeat the manipulations daily for 10 days.

Children. There is no experience with the use of the drug in children.

Overdose. May result in an intensification of adverse reactions.

Side effects.

Allergic reactions (possibly delayed) may occur during the use of the medication, including rash, itching, angioedema, hyperemia.

Gastrointestinal tract: irritation of the oral mucosa, nausea, vomiting.

Nervous system: headache, dizziness.

Shelf life. 3 years.

Storage conditions. Store at a temperature not exceeding 25 °C in the original packaging. Protect from direct sunlight.

Keep out of reach of children.

Packaging. 15 ml in a container with a spray pump in a carton.

Prescription status. Over-the-counter (without prescription).

Manufacturer.

Limited Liability Company "Experimental Plant "GNCLS".

LIMITED LIABILITY COMPANY "CORPORATION "ZDOROVYA".

Manufacturer's address and place of business.

8 Vorobiova Street, Kharkiv, Kharkiv Oblast, 61057, Ukraine.

(Limited Liability Company "Experimental Plant "GNCLS")

22 Shevchenka Street, Kharkiv, Kharkiv Oblast, 61013, Ukraine.

(LIMITED LIABILITY COMPANY "CORPORATION "ZDOROVYA")